Assessing Market Potential
Leveraging a Scientific Approach to Assess the Clinical Landscape and Market Opportunity for Three Biologic Agents in the Heme Malignancy Space
The Challenge
An emerging oncology company with a robust pipeline of agents was seeking to evaluate the US oncology/hematology landscape across three preclinical assets, in furtherance of the company’s corporate interests and portfolio development.
The company sought to assess the current and future competitive landscape, unmet clinical need, and prioritization of indications to pursue, in consideration of market potential and Phase 1/2 trial design.
The IP Solution
Taking a scientific approach to evaluating the competitive landscape, Innovation Partners provided a thorough assessment of the current/future competitive landscape across potential indications by conducting a comprehensive literature review.
Assumptions were tested by conducting primary market research with KOLs to understand perceptions and potential utilization scenarios.
The Results
Ultimately, the research resulted in the delivery of a dynamic sales forecasting model which was leveraged to determine the development strategy for the assets. Two of the three assets were moved into Phase 1 Studies, and the third was removed from consideration based on data provided in the forecasting models.
